Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18127457 | 0.83 | HRH2 (0.47) | NAAAHRH2 | |
| SCHEMBL18127483 | 0.80 | HRH2 (0.46) | NAAAHRH2 | |
| SCHEMBL18127459 | 0.78 | MMP12 (0.40) | NAAA | |
| SCHEMBL18123839 | 0.78 | ADORA3 (0.34) | HRH2 | |
| SCHEMBL18127505 | 0.78 | FAAH (0.30) | — | |
| SCHEMBL17518395 | 0.78 | CYP2C19 (0.32) | — | |
| SCHEMBL6164386 | 0.77 | NAAA (0.38) | NAAA | |
| SCHEMBL18127475 | 0.77 | CYP1A2 (0.42) | HRH2 | |
| SCHEMBL18123857 | 0.77 | FDPS (0.41) | — | |
| SCHEMBL18127484 | 0.77 | HTT (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170007664-A1 | CYCLIC DEPSIPEPTIDE COMPOUNDS AND THEIR USES | CYPRALIS LIMITED (GB) | 2017-01-12 | — | — | US | disclosed |
| US-20160289271-A1 | Cyclosporins Modified on the MeBmt Sidechain by Heterocyclic Rings | ALLERGAN, INC. | 2016-10-06 | — | — | US | disclosed |
| US-9382295-B2 | Cyclic depsipeptide compounds and their uses | CYPRALIS LIMITED (GB) | 2016-07-05 | — | — | US | disclosed |
| US-20150259386-A1 | CYCLIC DEPSIPEPTIDE COMPOUNDS AND THEIR USES | CYPRALIS LIMITED (GB) | 2015-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170007664-A1 | CYCLIC DEPSIPEPTIDE COMPOUNDS AND THEIR USES | FKBP14, FKBP1A, PIN1 | NAAA 3272/4885HRH2 2966/4885 |
| US-20160289271-A1 | Cyclosporins Modified on the MeBmt Sidechain by Heterocyclic Rings | CHP1, UACA, CRYAB | NAAA 4657/4885HRH2 588/4885 |
| US-20150259386-A1 | CYCLIC DEPSIPEPTIDE COMPOUNDS AND THEIR USES | FKBP14, FKBP1A, PIN1 | NAAA 3272/4885HRH2 2966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.